Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
HRTX Heron Therapeutics	$1.32 -28.3%	$2.00	$1.04 ▼ $2.68	$280.72M	1.15	938,249 shs	14.95 million shs
INZY Inozyme Pharma	$4.00	$3.99	$0.72 ▼ $6.24	$258.25M	2.27	960,267 shs	N/A
LFCR Lifecore Biomedical	$7.24 -6.7%	$7.46	$3.68 ▼ $8.85	$287.32M	0.65	122,856 shs	171,759 shs
VNRX VolitionRx	$0.64 +0.5%	$0.69	$0.40 ▼ $0.94	$66.76M	1.26	195,362 shs	56,031 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
HRTX Heron Therapeutics	-28.26%	-21.89%	-40.81%	-37.44%	-34.00%
INZY Inozyme Pharma	0.00%	0.00%	0.00%	+244.83%	-7.19%
LFCR Lifecore Biomedical	-6.70%	+3.58%	-11.17%	+3.87%	+50.21%
VNRX VolitionRx	+0.45%	+0.31%	-2.87%	+28.40%	+17.67%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
HRTX Heron Therapeutics	3.8604 of 5 stars	3.5	1.0	0.0	4.2	2.6	1.7	0.6
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	0.9593 of 5 stars	1.3	0.0	0.0	0.0	2.7	4.2	0.6
VNRX VolitionRx	2.5531 of 5 stars	3.5	0.0	0.0	0.0	3.5	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
HRTX Heron Therapeutics	3.00	Buy	$4.50	240.91% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside
LFCR Lifecore Biomedical	2.50	Moderate Buy	$8.00	10.50% Upside
VNRX VolitionRx	3.00	Buy	$3.50	445.17% Upside

Current Analyst Ratings Breakdown

Latest VNRX, LFCR, INZY, and HRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$4.00 ➝ $3.00
7/17/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/9/2025	VNRX VolitionRx	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/10/2025	VNRX VolitionRx	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$3.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
5/21/2025	LFCR Lifecore Biomedical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00

(Data available from 8/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
HRTX Heron Therapeutics	$144.29M	1.40	N/A	N/A	($0.22) per share	-6.00
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A
LFCR Lifecore Biomedical	$128.87M	2.08	N/A	N/A	$0.37 per share	19.57
VNRX VolitionRx	$1.31M	51.02	N/A	N/A	($0.11) per share	-5.84

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
HRTX Heron Therapeutics	-$13.58M	-$0.06	N/A	N/A	N/A	-5.24%	N/A	-3.43%	8/11/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	N/A
LFCR Lifecore Biomedical	$12.01M	-$1.45	N/A	N/A	N/A	-31.70%	-696.62%	-12.94%	10/3/2025 (Estimated)
VNRX VolitionRx	-$35.32M	-$0.27	N/A	∞	N/A	-2,321.14%	N/A	-163.39%	N/A

Latest VNRX, LFCR, INZY, and HRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/25/2025	Q4 2025	LFCR Lifecore Biomedical	-$0.09	N/A	N/A	N/A	$35.36 million	N/A
8/11/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	-$0.02	-$0.01	-$0.02	$38.08 million	N/A
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
LFCR Lifecore Biomedical	N/A	N/A	N/A	N/A	N/A
VNRX VolitionRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
HRTX Heron Therapeutics	N/A	2.40	1.76
INZY Inozyme Pharma	0.65	2.19	2.19
LFCR Lifecore Biomedical	66.36	2.71	1.59
VNRX VolitionRx	N/A	0.22	0.22

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
HRTX Heron Therapeutics	80.01%
INZY Inozyme Pharma	88.30%
LFCR Lifecore Biomedical	83.36%
VNRX VolitionRx	8.09%

Insider Ownership

Company	Insider Ownership
HRTX Heron Therapeutics	5.86%
INZY Inozyme Pharma	12.18%
LFCR Lifecore Biomedical	32.20%
VNRX VolitionRx	10.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
HRTX Heron Therapeutics	300	152.56 million	143.62 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable
LFCR Lifecore Biomedical	690	37.03 million	25.10 million	Optionable
VNRX VolitionRx	80	103.98 million	80.80 million	Optionable

VNRX, LFCR, INZY, and HRTX Headlines

Recent News About These Companies

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update | ...

August 8 at 9:08 AM | gurufocus.com

VolitionRx Limited Schedules Second Quarter 2025 Earnings Conference Call and Business Update

August 8 at 8:30 AM | prnewswire.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 78,125 Shares of Stock

August 7 at 10:59 AM | marketbeat.com

Cameron John Reynolds Buys 78,125 Shares of VolitionRx Limited (NYSE:VNRX) Stock

August 7 at 10:59 AM | marketbeat.com

VolitionRx Limited (NYSE:VNRX) Director Acquires $50,000.00 in Stock

August 7 at 8:02 AM | insidertrades.com

VolitionRx Announces Pricing of $1.2 Million Registered Direct Offering

August 4, 2025 | prnewswire.com

VolitionRx (NYSE:VNRX) Given "Buy" Rating at D. Boral Capital

July 17, 2025 | marketbeat.com

Nu.Q® Discover Expands Global Adoption and Epigenetic Innovation

July 16, 2025 | prnewswire.com

VolitionRx Limited (VNRX) - Yahoo Finance

July 11, 2025 | nz.finance.yahoo.com

Volition Announces Groundbreaking Lateral Flow Test for Point-of-Care Quantification of Nucleosomes

July 8, 2025 | prnewswire.com

Volition Announces MARS Consortium Clinical Study Suggests Nu.Q® H3.1. Concentrations are Closely Associated with Sepsis and Organ Failure

June 12, 2025 | prnewswire.com

Jones Trading Initiates Coverage of VolitionRx (VNRX) with Buy Recommendation

June 11, 2025 | msn.com

VolitionRx director Guy Innes buys $10,772 in common stock

June 5, 2025 | investing.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Director Buys 20,000 Shares of Stock

June 5, 2025 | insidertrades.com

Volition Announces Two Oral Presentations at Asian Meeting of Animal Medicine Specialties

June 4, 2025 | prnewswire.com

VolitionRX shares hold as Benchmark maintains rating

May 21, 2025 | uk.investing.com

VolitionRx Limited (AMEX:VNRX) Q1 2025 Earnings Call Transcript

May 20, 2025 | msn.com

Insider Buying: VolitionRx Limited (NYSE:VNRX) Insider Acquires 50,000 Shares of Stock

May 20, 2025 | insidertrades.com

VolitionRx Limited Announces Successful Detection of Nucleosomes in Cats

May 19, 2025 | prnewswire.com

VolitionRX aims for cash flow neutrality in 2025 as human diagnostics licensing advances

May 16, 2025 | msn.com

VolitionRX Limited (VNRX) Q1 2025 Earnings Call Transcript

May 16, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VNRX, LFCR, INZY, and HRTX Company Descriptions

Heron Therapeutics NASDAQ:HRTX

$1.32 -0.52 (-28.26%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.38 +0.06 (+4.55%)

As of 08/8/2025 07:49 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Inozyme Pharma NASDAQ:INZY

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Lifecore Biomedical NASDAQ:LFCR

$7.24 -0.52 (-6.70%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$7.28 +0.04 (+0.48%)

As of 08/8/2025 04:10 PM Eastern

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

VolitionRx NYSE:VNRX

$0.64 +0.00 (+0.45%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.64 -0.01 (-1.09%)

As of 08/8/2025 05:15 PM Eastern

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time